MedTrace Logo

Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Breast Cancer

NCT03113019 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-04-13

No results posted yet for this study

Summary

The purpose of this work: to assess the tolerability and effectiveness of the autogemotherapy method on the basis of autologous antigen-activated dendritic cells in the treatment of patients with breast cancer.

This technology is intended for complex treatment of patients with breast cancer and is aimed at preventing the occurrence and treatment of secondary foci. The need for this technology is justified by the widespread occurrence of breast cancer among women, a decrease in the average age at onset of the disease and a young age, and the chemoresistantness of locally advanced forms of cancer.

Conditions

Interventions

BIOLOGICAL

Immunotherapy based on dendritic cells

Intravenous injection of cells

Sponsors & Collaborators

  • Research Institute of Fundamental and Clinical Immunology

    lead OTHER_GOV

Principal Investigators

  • Sergey V. Sennikov, MD · RIFCI

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
28 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-11
Primary Completion
2017-02-11
Completion
2017-09-11

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03113019 on ClinicalTrials.gov